These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7000222)

  • 1. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.
    Jacobi GH; Altwein JE; Kurth KH; Basting R; Hohenfellner R
    Br J Urol; 1980 Jun; 52(3):208-15. PubMed ID: 7000222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
    J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
    Sander S; Nissen-Meyer R; Aakvaag A
    Scand J Urol Nephrol; 1982; 16(3):193-7. PubMed ID: 6219455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author's transl)].
    Spona J; Lunglmayr G
    Wien Klin Wochenschr; 1980 Jul; 92(14):494-7. PubMed ID: 6933738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
    Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
    Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A morphological study on the effect of cyproterone acetate on human prostatic carcinoma.
    Tveter KJ; Attramadal A; Hannestad R; Otnes B
    Scand J Urol Nephrol; 1979; 13(3):237-43. PubMed ID: 531525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striking regression of advanced prostatic carcinoma induced by cyproterone acetate (Androcur). A case report.
    Varenhorst E; Björnlert U; Carlström K
    Scand J Urol Nephrol; 1981; 15(2):157-9. PubMed ID: 7330610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.
    de Voogt HJ; Smith PH; Pavone-Macaluso M; de Pauw M; Suciu S
    J Urol; 1986 Feb; 135(2):303-7. PubMed ID: 2935644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with cyproterone acetate in a randomised and in an open trial.
    Tunn UW; Weiglein W; Saborowski J; Senge T
    Prog Clin Biol Res; 1987; 243A():365-8. PubMed ID: 2958860
    [No Abstract]   [Full Text] [Related]  

  • 10. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
    Schroeder FH
    Prostate; 1984; 5(2):193-8. PubMed ID: 6231535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogens in the treatment of prostatic cancer.
    Bracci U
    Eur Urol; 1979; 5(5):303-6. PubMed ID: 446504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oestrogen or cyproterone acetate treatment on adrenocortical function in prostate carcinoma patients.
    Schürmeyer T; Graff J; Senge T; Nieschlag E
    Acta Endocrinol (Copenh); 1986 Mar; 111(3):360-7. PubMed ID: 2421511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
    Irani J; Salomon L; Oba R; Bouchard P; Mottet N
    Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
    Aubert J; Dore B; Irani J; Bon D
    J Urol (Paris); 1990; 96(8):431-5. PubMed ID: 1707083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.
    Giuliani L; Pescatore D; Giberti C; Martorana G; Natta G
    Eur Urol; 1980; 6(3):145-8. PubMed ID: 7371659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproterone acetate in the management of prostatic cancer.
    Tunn UW
    Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
    [No Abstract]   [Full Text] [Related]  

  • 19. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 20. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.